Fulgent Genetics Earnings Perspective: Return On Capital Employed
Portfolio Pulse from Benzinga Insights
Fulgent Genetics (NASDAQ:FLGT) reported Q1 sales of $66.17 million and an overall loss of $15.85 million. The company posted a negative Return On Capital Employed (ROCE) of -0.01%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.22, beating analyst predictions of $-0.43.
May 19, 2023 | 2:55 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Fulgent Genetics reported Q1 sales of $66.17 million and a loss of $15.85 million. The company's negative ROCE of -0.01% suggests inefficient capital allocation, which may impact stock price.
Fulgent Genetics' negative ROCE of -0.01% indicates that the company is not effectively allocating its capital, which could negatively impact its stock price. Additionally, the company reported a loss in Q1, which may also contribute to a decline in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100